Evocalcet

Evocalcet
Clinical data
Trade names	Orkedia
Identifiers
	IUPAC name 2-[4-[(3S)-3-[[(1R)-1-Naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]acetic acid;
CAS Number	870964-67-3;
PubChem CID	71242808;
DrugBank	DB12388;
UNII	E58MLH082P;
KEGG	D11063;
Chemical and physical data
Formula	C24H26N2O2
Molar mass	374.484 g·mol−1

Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism.^[1] It acts as a calcium-sensing receptor agonist.^[2]

In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.^[3]

References[edit]

^ Kawata, Takehisa; Tokunaga, Shin; Murai, Miki; Masuda, Nami; Haruyama, Waka; Shoukei, Youji; Hisada, Yutaka; Yanagida, Tetsuya; Miyazaki, Hiroshi; Wada, Michihito; Akizawa, Tadao; Fukagawa, Masafumi (2018). "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE. 13 (4): e0195316. doi:10.1371/journal.pone.0195316. PMC 5882164. PMID 29614098.
^ Miyazaki, Hiroshi; Ikeda, Yousuke; Sakurai, Osamu; Miyake, Tsutomu; Tsubota, Rie; Okabe, Jyunko; Kuroda, Masataka; Hisada, Yutaka; Yanagida, Tetsuya; Yoneda, Hikaru; Tsukumo, Yukihito; Tokunaga, Shin; Kawata, Takehisa; Ohashi, Rikiya; Fukuda, Hajime; Kojima, Koki; Kannami, Ayako; Kifuji, Takayuki; Sato, Naoya; Idei, Akiko; Iguchi, Taku; Sakairi, Tetsuya; Moritani, Yasunori (2018). "Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters. 28 (11): 2055–2060. doi:10.1016/j.bmcl.2018.04.055.
^ "Kyowa Hakko Kirin Launches ORKEDIA® TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.